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Introduction
Intraductal papillary mucinous neoplasms (IPMN) are common
pancreatic cystic tumors characterized by a pathological prolif-
eration of mucin-producing epithelial cells with an increased
risk of pancreatic cancer. Overproduction of mucus results in
cystic or saccular dilations of the pancreatic ductal system.
IPMN may involve the branch ducts (BD-IPMN), the main duct
(MD-IPMN), or both (mixed-IPMN) [1]. IPMN is suspected to
cause acute or recurrent pancreatitis (RP) in 7–67% of cases
[2–4]. Obstruction of the pancreatic duct (PD) by highly vis-
cous mucus is postulated to determine the development of
pancreatitis.
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ABSTRACT
Background and study aims Pancreatic intraductal papil-
lary mucinous neoplasms (IPMN) are cystic tumors of the
pancreas characterized by a malignant potential. IPMN
have been associated with recurrent pancreatitis (RP). Ob-
struction of the main pancreatic duct by thick mucus has
been postulated to be the cause of pancreatitis. In a few
isolated reports, pancreatic sphincterotomy (PS) has been
reported to reduce the frequency of pancreatitis. The aim
of this study was to assess the efficacy of PS in patients
with IPMN-associated RP.
Patients and methods We retrospectively identified pa-
tients with RP and IPMN who underwent PS from June
2010 to December 2015. Patients were included in two dif-
ferent groups: (a) main duct/mixed type IPMN (MD-IPMN)
and (b) branch duct IPMN (BD-IPMN) with or without worri-
some features/high risk stigmata. Other causes of RP were
excluded. The number of pancreatitis episodes occurring
during a comparable time period before and after PS was
evaluated.
Results In total, 16 patients were analyzed (seven included
in the MD-IPMN group and nine in the BD-IPMN group). The
numbers of pancreatitis episodes occurring before and
after PS were 3.5 ±2.32 and 0.56±1.03, respectively (P <
0.0001). Mean follow-up was 27.4 months (range 6–63
months). Complete, partial (reduction of pancreatitis
episodes >50%), and no response were obtained in 11
(68.7%), 3 (18.7%), and 2 patients (12.5%), respectively.
One (6.25%) case of mild post-endoscopic retrograde cho-
langiopancreatography (ERCP) pancreatitis was observed.
No cancer was detected in resected patients. None of the
BD-IPMN group patients had or developed worrisome fea-
tures/high risk stigmata during follow-up.
Conclusions PS seems to be effective in reducing the
number of episodes of IPMN-associated pancreatitis and
should be considered as a treatment option in selected clin-
ical settings. However, active surveillance should be contin-
ued considering the malignant potential of IPMN. Further
prospective controlled studies are needed to confirm our
results.
* Drs Bernardoni and Crinò contributed equally to this article.
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IPMN-associated RP may worsen a patient’s quality of life
and progresses to chronic pancreatitis. Moreover, some au-
thors have suggested a higher risk of malignancy in IPMN caus-
ing acute pancreatitis. Therefore, pancreatitis may indicate the
need for surgical resection even when there are no signs of ma-
lignancy by imaging or cytology as reported in the Fukuoka
consensus [5]. However, pancreatic surgery has a high inci-
dence of complications and mortality even when performed at
high volume centers. Moreover, surgical risks are increased in
elderly patients with comorbidities.
Based on the postulated IPMN-associated pancreatitis pa-
thophysiology, we hypothesized that pancreatic sphincterot-
omy (PS) facilitates mucus outflow into the duodenum, reduces
the intraductal pressure, and reduces pancreatitis episodes.
However, to date, only a few isolated cases examining this hy-
pothesis have been reported [6–8]. We conducted a retrospec-
tive study to assess the safety and efficacy of PS in reducing the
frequency of IPMN-associated pancreatitis.
Patients and methods
Study approval and patient population
This study was approved by the Verona University Hospital Eth-
ics Committee (Prot.n.5006).
We retrospectively selected patients with IPMN diagnosis
and RP who underwent PS from June 2010 to December 2015
using our prospectively collected endoscopic retrograde cho-
langiopancreatography (ERCP) database.
Diagnosis of IPMN was achieved by:
1. Cytology after endoscopic ultrasound-guided fine-needle
aspiration, when performed.
2. MRI with magnetic resonance cholangiopancreatography
(MRCP) with or without secretin injection and/or endoscopic
ultrasound (EUS). Imaging criteria used to diagnose IPMN
were: (a) presence of one or more dilated branch ducts
(≥10mm) communicating with a non-dilated (< 5mm) PD
(BD-IPMN); (b) presence of a segmental or diffusely dilated
PD (≥5mm) with no dilation of secondary ducts (MD-IPMN);
(c) presence of a dilated PD (≥5mm) communicating with
one or more dilated branch ducts (mixed-IPMN).
3. ERCP findings: (a) spontaneous extruding mucus from the
papilla (“fish-eye”); (b) mucus extrusion from the papillary
orifice after sphincterotomy or intraductal injection of con-
trast medium; (c) mucinous filling defects in the main pan-
creatic duct (linear filling defect during low pressure pan-
creatography); (d) cystic pancreatic branch duct opacifica-
tion.
Definitive differential diagnosis between MD-IPMN and chronic
pancreatitis (CP) was achieved by previously described ERCP
findings (points [a] and/or [b] and/or [c]).
Acute pancreatitis was defined as abdominal pain associated
with three times more than the upper normal limit for serum
pancreatic enzymes (i. e. amylases or lipases) and/or pancreati-
tis at imaging (CT or MRI). RP was defined as having at least two
episodes of pancreatitis that resulted in hospital admission dur-
ing the last 2 years.
Exclusion criteria
Patients with other causes of recurrent pancreatitis were ex-
cluded: (a) suspected biliary etiology (episodic jaundice and/or
transient elevation of liver function tests and/or evidence of
gallbladder/choledochal stones or sludge at MRI or EUS [9]);
(b) alcohol use (> 40g/day [10]); (c) smoking (> 12 pack-years
[11]); (d) pancreas divisum with santorinicele at MRI [12]; (e)
autoimmune pancreatitis according to the International
Consensus Diagnostic Criteria [13]; (f) hypertriglyceridemia
(> 1000mg/dL) [14]; (g) associated gene mutations (CFTR,
SPINK1, PRSS1, CTRC) and/or with a family history of pancreati-
tis [15]; (h) consumption of medication associated with acute
pancreatitis [16]; (i) presence of CP changes at MRI [17] and/
or at endoscopic pancreatography (≥grade 2 according to the
Cambridge classification [18]).
Furthermore, patients with less than 6 months follow-up
after PS were excluded.
Outcome measures
Epidemiological data, IPMN features (type, location, and size),
ERCP findings and related adverse events, and the number of
pancreatitis episodes that occurred before and after endo-
scopic treatment were recorded for each patient.
We assessed the number of pancreatitis episodes that oc-
curred before PS using historical medical documentation
provided by patients at the time of hospitalization.
Pancreatitis episodes occurring after PS were assessed both
by reviewing the medical records of the scheduled follow-up
visits and by phone contact in all patients. At our institution,
patients treated with PS for IPMN-associated pancreatitis are
actively followed by medical visits or phone contact (based on
patients preference) 6 months after the procedure and then
yearly. In both cases, we investigated abdominal pain recur-
rence, any emergency room access, or hospitalization or la-
boratory/imaging examination performed after PS. The medical
documentation provided by the patients was analyzed and
acute pancreatitis episodes fulfilling the previously reported
criteria were recorded.
We defined “complete response” as the absence of pancrea-
titis during follow-up.A “partial response” was defined as a re-
duction>50% of pancreatitis episodes after PS.
Patients were classified into two groups: MD-IPMN (includ-
ing mixed type IPMN) and BD-IPMN (with or without worrisome
features).
Endoscopic procedures
All endoscopic procedures were performed under general anes-
thesia with a lateral-viewing duodenoscope (TJF-160 and TJF-
180; Olympus, Tokyo, Japan). Hyoscine-butylbromide (40mg)
was injected intravenously to inhibit duodenal peristalsis.
Deep cannulation of the PD was achieved by a standard sphinc-
terotome both over the wire or by injection of contrast medi-
um; after pancreatography, a longest possible (based on the
anatomical landmark) guidewired selective pancreatic sphinc-
terotomy was performed. An ERBE EndoCut electroincision
was used in all patients. No plastic stent was inserted because
of the high risk of occlusion.
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Statistical analysis
Continuous variables were assessed for normality and express-
ed as means and standard deviation (SD). Paired Student’s t test
was used to compare the mean values of variables before and
after treatment. Categorical variables were expressed as fre-
quencies with percentages. The chi-squared test with Yates’
correction was used for categorical data. All tests were two-
tailed. Fisher’s exact test was used in a 2×2 table where applic-
able. Statistical significance was determined by a P value <0.05.
Data were analyzed using SPSS 22 software (SPSS, IBM, Chica-
go, United States).
Results
In total, 26 IPMN patients suffering from RP who underwent PS
were identified. Of these, 10 patients were excluded: 1 was lost
at follow-up, 2 were affected by pancreas divisum with santori-
nicele, 3 had signs of chronic pancreatitis, and 4 did not reach 6
months of follow-up after PS because they underwent pancre-
atic resection. Therefore, 16 patients (13 men and 3 women
with a mean age of 60.7 years [range 41–84 years]) were in-
cluded in our study and analyzed (▶Table1 and ▶Fig. 1).
Seven patients were included in the MD-IPMN group and nine
patients were included in the BD-IPMN group. All MD-IPMN pa-
tients underwent PS because severe comorbidities (≥ASA IV ac-
cording to the American Society of Anesthesiology’s Classifica-
tion) precluded surgery or patients refused resection. No high
risk stigmata/worrisome features were observed by imaging ac-
cording to the Fukuoka consensus [5] in patients with BD-IPMN.
ERCP findings were: spontaneous extruding mucus from the
papilla sign in 2 patients (the papilla orifice was not widely dila-
ted and PS was normally performed); mucus extrusion from the
papilla after PS in 4; PD dilation without strictures and cystic
branch duct opacification in 4; normal PD and cystic branch
duct opacification in 4; and normal pancreatography in 3 (▶Ta-
ble2). PS was performed at major papilla in 15 patients and at
minor papilla in 1 patient with a concomitant pancreas divisum.
No procedure-related mortality was observed. One patient
(6.25%) experienced a mild post-ERCP pancreatitis that was
managed within 3 days with medical therapy.
The mean follow-up for the study population was 27.4
months (range 6–66 months). The average number of pan-
creatitis episodes that occurred during the same interval of
time before and after PS were 3.5±2.32 and 0.56±1.03,
respectively (P<0.0001).
The mean follow-up times for the MD-IPMN and BD-IPMN
groups were 23.4 months and 30.4 months, respectively. The
average number of pancreatitis episodes that occurred during
a period of time equal to the follow-up before and after endo-
scopic treatment in the MD-IPMN and BD-IPMN groups were 3±
1.41 and 0.57±1.13 (P=0.015), and 3.89±2.85 and 0.56±1.01
(P=0.014), respectively (▶Table3 and ▶Fig. 2).
▶ Table 1 Demographic and clinical features of patients analyzed.
No. of patients 16
Age, mean (range), years 61 (41–84)
Sex, male/female 13/3
Indication for PS, n (%)
▪ MD-IPMN unfit for/refusing surgery 7 (44%)
▪ BD-IPMN without worrisome feature 9 (56%)
Type of IPMN, n (%)
▪ MD-IPMN 2 (13%)
▪ BD-IPMN 9 (56%)
▪ Mixed-IPMN 5 (31%)
Location (and MD mean size) of MD/mixed-IPMN, n (%)
▪ Head (6.5mm) 6 (86%)
▪ Body 0 (0%)
▪ Tail 0 (0%)
▪ Diffuse (7mm) 1 (14%)
Location (and mean size) of BD-IPMN, n (%)
▪ Head–Uncinate (13mm) 8 (89%)
▪ Body (10mm) 1 (11%)
▪ Tail 0 (0%)
PS, pancreatic sphincterotomy; MD-IPMN, main duct/mixed type intraductal
papillary mucinous neoplasm; BD-IPMN, branched duct intraductal papillary
mucinous neoplasm.
26 patients with IPMN-related recurrent pancreatitis 
underwent PS
MD-IPMN group
7 patients
mean follow-up 
23.4 months
BD-IPMN group
9 patients
mean follow-up 
30.4 months
5 complete response (72%)
1 partial response (14%)
1 no response (14%)
6 complete response (67%)
2 partial response (22%)
1 no response (11%)
16 patients analyzed
10 patients excluded:
–3 signs of chronic pancreatitis
–2 pancreas divisum with santorinicele
–1 lost at follow-up
–4 follow-up <6 months 
▶ Fig. 1 Study flow chart of the patients analyzed. PS, pancreatic
sphincterotomy. MD-IPMN, main duct/mixed type intraductal pap-
illary mucinous neoplasm; BD-IPMN, branched duct intraductal
papillary mucinous neoplasm.
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A complete response was observed in 11 patients (68.7%,
mean follow-up 24.9 months, range 6–66months). A partial re-
sponse was found in three patients (18.7%, mean follow-up 40.6
months, range 11–63 months). These three patients experi-
enced only one episode of pancreatitis during the follow-up.
For comparison, these patients had five, four, or three pancrea-
titis episodes that occurred during an equivalent period of time
before PS.No response was observed in two patients (12.5%,
▶ Table 2 Main ERCP findings of the 16 patients analyzed stratified by IPMN type.
MD-IPMN (n=2) Mixed-IPMN (n=5) BD-IPMN (n=9)
Spontaneous extruding mucus from the papilla 2
Mucus extrusion after PS 1 1 2
PD mucinous filling defects1 1
PD dilation without strictures + cystic branch duct opacification 3
Cystic branch duct opacification 3
Normal 3
PD, pancreatic duct; PS, pancreatic sphincterotomy; MD-IPMN, main duct/mixed type intraductal papillary mucinous neoplasm; BD-IPMN, branched duct intraductal
papillary mucinous neoplasm.
1 PD linear filling defect during low pressure pancreatography.
▶ Table 3 Primary outcome and follow-up of whole population and in the three groups. Time before pancreatic sphincterotomy (PS) was calculated in
each single patient based on the length of the maximum follow-up available. Time before and after PS, were therefore identical in every single patient.
Number of pancreatitis episodes (mean±SD) P value1 Follow-up mean (range), months
Before PS After PS
All patients analyzed 3.50± 2.32 0.56± 1.03 <0.0001 27.4 (6–63)
MD-IPMN 3±1.41 0.57± 1.13 0.0149 23.4 (6–48)
BD-IPMN 3.89± 2.85 0.56± 1.01 0.0142 30.4 (7–63)
PS, pancreatic sphincterotomy; MD-IPMN, main duct/mixed type intraductal papillary mucinous neoplasm; BD-IPMN, branched duct intraductal papillary mucinous
neoplasm.
1 Paired t test.
Before PS After PS
MD-IPMN
a
P = 0.0149
6
5
4
3
2
1
0
Before PS After PS
BD-IPMN
b
P = 0.0142
12
10
8
6
4
2
0
▶ Fig. 2 Number of pancreatitis episodes (ordinate) calculated in a comparable time before and after pancreatic sphincterotomy (PS).
aMD-IPMN group (n =7); b BD-IPMN group (n=9). P=paired t test. MD-IPMN, main duct/mixed type intraductal papillary mucinous neoplasm;
BD-IPMN, branched duct intraductal papillary mucinous neoplasm.
Bernardoni Laura et al. Preliminary experience with… Endoscopy International Open 2017; 05: E1144–E1150 E1147
Th
is
 d
oc
um
en
t w
as
 d
ow
nl
oa
de
d 
fo
r p
er
so
na
l u
se
 o
nl
y.
 U
na
ut
ho
riz
ed
 d
ist
rib
ut
io
n 
is 
st
ric
tly
 p
ro
hi
bi
te
d.
mean follow-up 21 months, range 16–26 months). These two
patients experienced three pancreatitis episodes each during
the follow-up compared with three and two episodes occurring
during an equivalent period of time before PS.
Two patients underwent surgical resection during follow-up:
▪ One patient with no response after PS in the MD-IPMN group
underwent total pancreatectomy 16 months after sphinc-
terotomy. This patient became fit for surgery because of a
significant clinical improvement after a cerebral vascular ac-
cident. Histology showed high grade dysplasia of the main
duct epithelium.
▪ One patient from the BD-IPMN group underwent pylorus-
preserving pancreatoduodenectomy after 26 months be-
cause of a suspicion of main duct involvement and no re-
sponse to PS.Histology showed low grade dysplasia of the
ductal epithelium.
IPMN diagnosis was confirmed in both resected patients and no
invasive carcinoma was observed histologically.
No statistically significant difference was found between re-
sponse and type of neoplasm (BD-IPMN vs. MD-IPMN) (P=1).
Furthermore, no relationship was found between response and
dilation of the PD (5–9mm vs ≥10mm) (P=1) (▶Table4).
Interestingly, none of the BD-IPMN group patients had or
developed worrisome features/high risk stigmata during fol-
low-up.On the other hand, follow-up data were not available
for the MD-IPMN group patients because surveillance was stop-
ped due to their unfit-for-surgery condition.
Discussion
The results of our preliminary study suggest that PS is effective
in preventing pancreatitis relapses in patients with IPMN and
RP. In the literature, only six cases of IPMN-associated pancrea-
titis successfully treated with PS are described [6–8]. In 1998,
Elton et al. [7] reported three cases where PS resulted in the re-
solution of symptoms in “mucinous ductal ectasia” patients.
More recently, Oh and Dua [6] described two cases of IPMN-
related RP, both of which improved after PS. In the present
study, complete or partial responses were observed in 85% of
patients during a mean follow-up of 22 months.
PS has been proposed for patients with MD-IPMD or BD-
IPMN. For MD-IPMN, obstruction of the PD by mucus is largely
accepted [19, 20]. Obstruction of the PD by thick mucus leads
to ductal hypertension, which is responsible for premature re-
lease and activation of pancreatic enzymes. This same mecha-
nism has also been postulated for BD-IPMN; in these cases, mu-
cin is suspected to migrate into the main duct [21]. The efficacy
of PS in BD-IPMN seems to confirm this hypothesis. However,
our study’s patient population was limited in size and type.
Therefore, we cannot draw any definitive conclusions because
this sample population was not representative of all IPMN pa-
tients. PS clearly does not change the IPMN-associated risk of
cancer and survival. Therefore, the aim of performing PS in pa-
tients unfit for surgery and in patients with BD-IPMN without
worrisome features/high risk stigmata is to improve patient’s
quality of life and to avoid pancreatic surgery in patients with-
out malignant features at imaging, respectively. Interestingly,
four of the excluded patients were treated with “bridge to sur-
gery” aim. While these patients wait for treatment by tertiary
care centers with long waiting lists, a high frequency of pan-
creatitis may increase the risk of delaying surgery even further.
PS may prevent or reduce the recurrence of pancreatitis which
would allow the centers to perform surgery at the scheduled
time.
However, the most important result from our study was ob-
served in patients with BD-IPMN who had no evidence of PD in-
volvement/high risk stigmata/worrisome features at imaging.
Indeed, these patients should undergo surgical resection even
in the absence of any signs of malignancy, according to interna-
tional guidelines [5]. This is particularly relevant in cases invol-
ving older patients or where lesions are located in the pancreat-
ic head, requiring duodenopancreatectomy. PS seems to be an
effective treatment for this group of patients because we ob-
▶ Table 4 Correlation between clinical outcomes, type of IPMN and dilation of the main duct. Mean follow-up of responders and not responders after
PS.
Responders1 Not responders P value2
n (%) 14 (88%) 2 (12%)
Type of IPMN
▪ BD-IPMN 8 (57%) 1 (50%) 1
▪ MD-IPMN 6 (42%) 1 (50%)
Main duct dilation
▪ 5–9mm 6 (78%) 1 (100%)
▪ ≥10mm 1 (22%) 0 1
Follow-up, mean (range) 28.2 (6–66) 21 (16–26) –
MD-IPMN, main duct/mixed type intraductal papillary mucinous neoplasm; BD-IPMN, branched duct intraductal papillary mucinous neoplasm.
1 Including complete and partial responders.
2 Fischer exact test.
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served complete or partial responses in 89.9% of patients. In
other words, PS should reduce the need for resective pancreatic
surgery in patients with BD-IPMN; however, pancreatitis may be
a sign of malignancy, and surgery may be required regardless of
the presence of high risk stigmata/worrisome features. How-
ever, the association between pancreatitis and malignant IPMN
is still debated. Pancreatitis seems to increase the risk for ma-
lignancy in retrospective surgical series, even for BD-IPMN
[22, 23]; however, the findings from preoperative imaging are
not reported in these studies and the presence of other poten-
tial causes of pancreatitis (e. g. alcohol, chronic pancreatitis,
etc.) was not excluded. Indeed, the risk for malignancy does
not seem to increase in one medical series as well as in two
other surgical studies after exclusion of other causes of pan-
creatitis [2, 24, 25]. In our series, the nine patients in the BD-
IPMN group did not have any evidence of high risk stigmata/
worrisome features. Only one of these patients underwent sur-
gery for involvement of PD and this patient’s surgical specimen
showed histological evidence of low grade dysplasia. The re-
maining eight patients did not show any morphological chang-
es during a mean follow-up of 31 months and they are still un-
der active radiologic surveillance. Further studies are needed to
confirm that pancreatitis does not increase the risk of malig-
nancy in BD-IPMN patients in the absence of high risk stigma-
ta/worrisome features.
In the present study, all BD-IPMN were located in the head of
the pancreas. Therefore, we may assume that the mucus pro-
duced by the neoplasm may easily migrate from the involved
branch duct to the pre-papillary PD leading to obstruction.
However, no definitive data are available and this hypothesis
should be considered to be purely speculative until the publica-
tion of a larger study. Indeed, IPMN of the tail seems to mani-
fest less frequently with pancreatitis [2, 24] and patients with
this form of IPMN undergo surgery that utilizes a laparoscopic
approach that is rarely contraindicated. Moreover, we believe
that PS would be less effective in patients with IPMN of the tail
because it is likely that the obstruction could occur along the
PD and distant from the papilla.
The major limitation of our study is the absence of a control
group.However, in Jang et al. [2], recurrence of pancreatitis
was observed in 50% of 10 patients with IPMN-associated pan-
creatitis not resected because of comorbidities. Our encoura-
ging results must be confirmed in larger, randomized con-
trolled trials. In conclusion, PS is safe and may be helpful in the
management of select patients with IPMN-associated pancrea-
titis.
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